Identification of Gut Microbial Lysine and Histidine Degradation and CYP-Dependent Metabolites as Biomarkers of Fatty Liver Disease
Open Access
- 28 February 2023
- journal article
- research article
- Published by American Society for Microbiology in mBio
- Vol. 14 (1), e0266322
- https://doi.org/10.1128/mbio.02663-22
Abstract
Because the high prevalence of nonalcoholic fatty liver disease sets diagnostic challenges to health care, identification of new biomarkers of the disease that in the future could have potential utility as diagnostic biomarkers of high liver fat content is important. Our results show that increased amino acid degradation products in the feces may be such biomarkers. Numerous studies have described specific metabolites as biomarkers of severe liver diseases, but very few have measured gut microbiota (GM)-produced metabolites in fatty liver disease. We aimed at finding GM signatures and metabolite markers in plasma and feces related to high liver fat content. Based on imaging, we divided study participants into low (5%, HF, n = 39) liver fat groups. Fecal (LF n = 14, HF n = 25) and plasma (LF n = 11, HF n = 7) metabolomes of subsets of participants were studied using liquid chromatography/high resolution mass spectrometry. The GM were analyzed using 16S rRNA gene sequencing. Additionally, blood clinical variables and diet were studied. Dyslipidemia, higher liver enzymes and insulin resistance characterized the HF group. No major differences in diet were found between the groups. In the GM, the HF group had lower abundance of Bacteroides and Prevotellaceae NK3B31 group than the LF group after adjusting for metformin use or obesity. In feces, the HF group had higher levels of lysine and histidine degradation products, while 6-hydroxybetatestosterone (metabolized by CYP3A4) was low. Higher plasma levels of caffeine and its metabolites in the HF group indicate that the activity of hepatic CYP1A2 was lower than in the LF group. Our results suggest, that low fecal Prevotellaceae NK3B31 and Bacteroides abundance, and increased lysine and histidine degradation may serve as GM biomarkers of high liver fat. Altered plasma caffeine metabolites and lowered testosterone metabolism may specify decreased CYP activities, and their potential utility, as biomarkers of fatty liver disease.IMPORTANCE Because the high prevalence of nonalcoholic fatty liver disease sets diagnostic challenges to health care, identification of new biomarkers of the disease that in the future could have potential utility as diagnostic biomarkers of high liver fat content is important. Our results show that increased amino acid degradation products in the feces may be such biomarkers. In the blood, molecules that indicate defective hepatic metabolic enzyme activities were identified in individuals with high liver fat content.Keywords
Funding Information
- Academy of Finland (272376)
- Academy of Finland (266286)
- Novo Nordisk Fonden (NNF20OC0060547)
- Diabetestutkimussäätiö
- Helsingin Yliopisto
- Helsinki University Hospital Government Research funds
- Finnish Cultural Foundation
- Academy of Finland (308042, 349264)
- Academy of Finland (335443)
- Academy of Finland (314383)
- Novo Nordisk Fonden (NNF17OC0027232)
- Novo Nordisk Fonden (NNF10OC1013354)
- Signe ja Ane Gyllenbergin Säätiö
- Suomen Lääketieteen Säätiö
- Varsinais-Suomen Sairaanhoitopiiri
- WRI | Jenny ja Antti Wihurin Rahasto
- Academy of Finland | Faculty of Sport and Health Sciences/ University of Jyväskylä (PACTS2)
This publication has 55 references indexed in Scilit:
- Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipidsDiabetologia, 2013
- Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver DiseaseCell Metabolism, 2012
- Liver Fat in the Pathogenesis of Insulin Resistance and Type 2 DiabetesDigestive Diseases, 2010
- Contribution of Gut Bacteria to Liver PathobiologyGastroenterology Research and Practice, 2010
- Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesityProceedings of the National Academy of Sciences of the United States of America, 2009
- Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver DiseaseDrug Metabolism and Disposition, 2009
- Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic PatientsDiabetes Care, 2007
- Influence of Hepatic Steatosis (Fatty Liver) on Severity and Composition of Dyslipidemia in Type 2 DiabetesDiabetes Care, 2006
- Human Cytochrome P450: Metabolism of Testosterone by CYP3A4 and Inhibition by KetoconazoleCurrent Protocols in Toxicology, 2004
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985